| Differences in DNA condensation and release by lysine and arginine homopeptides govern their DNA delivery efficiencies A Mann, G Thakur, V Shukla, AK Singh, R Khanduri, R Naik, Y Jiang, ... Molecular pharmaceutics 8 (5), 1729-1741, 2011 | 89 | 2011 |
| Enhancer reprogramming confers dependence on glycolysis and IGF signaling in KMT2D mutant melanoma M Maitituoheti, EZ Keung, M Tang, L Yan, H Alam, G Han, AK Singh, ... Cell reports 33 (3), 2020 | 49 | 2020 |
| Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer AK Singh*, E Orouji*, AT Raman*, A Sorokin, E Arslan, AK Ghosh, ... Gut 71 (5), 938-949, 2022 | 29 | 2022 |
| Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy CJ Terranova, M Tang, M Maitituoheti, AT Raman, AK Ghosh, J Schulz, ... Cell reports 36 (3), 2021 | 20 | 2021 |
| Evaluation of epigenetic drug targeting of heterogenous tumor cell fractions using potential biomarkers of response in ovarian cancer AK Singh, N Chandra, SA Bapat Clinical Cancer Research 21 (22), 5151-5163, 2015 | 15 | 2015 |
| A tumor deconstruction platform identifies definitive end points in the evaluation of drug responses RR Naik, AK Singh, AM Mali, MF Khirade, SA Bapat Oncogene 35 (6), 727-737, 2016 | 14 | 2016 |
| Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor AD Bhalla, SM Landers, AK Singh, JP Landry, MG Yeagley, GSB Myerson, ... Laboratory Investigation 102 (6), 658-666, 2022 | 8 | 2022 |
| Dysregulation and epigenetic reprogramming of NRF2 signaling axis promote acquisition of cisplatin resistance and metastasis in head and neck squamous cell carcinoma AA Osman, E Arslan, M Bartels, C Michikawa, A Lindemann, K Tomczak, ... Clinical Cancer Research 29 (7), 1344-1359, 2023 | 7 | 2023 |
| Epigenetic Perspective of Immunotherapy for Cancers S Keshari*, P Barrodia*, AK Singh# Cells 12 (365), https://doi.org/10.3390/cells12030365, 2023 | 6 | 2023 |
| Transforming the future of treatment for ovarian cancer Y Dong, J Batra, K Anand, S Bapat, J Clements Clinical and Experimental Pharmacology 4 (3), Article number: 1571-9, 2014 | 6 | 2014 |
| Enhancer reprogramming in melanoma immune checkpoint therapy resistance M Maitituoheti, A Shi, M Tang, LL Ho, C Terranova, K Galani, EZ Keung, ... bioRxiv, 2022.08. 31.506051, 2022 | 3 | 2022 |
| KMT2D Loss Promotes Head and Neck Squamous Carcinoma Through Enhancer Reprogramming and Modulation of Immune Microenvironment SC Callahan, M Divenko, P Barrodia, AK Singh, E Arslan, Z Liu, J Yang, ... Biorxiv, 2021.09. 21.461314, 2021 | 3 | 2021 |
| Tsyn-seq: a T cell synapse–based antigen identification platform Y Jin, T Miyama, A Brown, T Hayase, X Song, AK Singh, L Huang, ... Cancer Immunology Research, 2024 | 1 | 2024 |
| Sirtuin 2 inhibition modulates chromatin landscapes genome-wide to induce senescence in ATRX-deficient malignant glioma JTH Prit Benny Malgulwar, Carla Danussi, Sharvari Dharmaiah, William Johnson ... Neuro-Oncology 155 (doi: 10.1093/neuonc/noad155), PMID: 37625115, 2023 | 1* | 2023 |
| New cellular models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor AD Bhalla, SM Landers, AK Singh, MG Yeagley, GSB Meyerson, ... bioRxiv, 2021.05. 13.443902, 2021 | 1 | 2021 |
| GENE-34. THERAPEUTICALLY TARGETING EPIGENOMIC AND TRANSCRIPTIONAL DYSFUNCTION IN ATRX-DEFICIENT GLIOMA C Danussi, A Singh, P Pinnamaneni, G Fisher, D Picketts, K Kannan, ... Neuro-Oncology 21 (Suppl 6), vi104, 2019 | 1 | 2019 |
| Elevated H3K27 trimethylation mediates adaptation to DNA demethylation in BRAFV600E-mutated colorectal cancer HM Lee, AK Saw, VK Morris, AK Singh, S Napolitano, A Sorokin, PK Marie, ... Cancer Research 84 (6_Supplement), 3241-3241, 2024 | | 2024 |
| Enhancers as targets for improvements in immunotherapy A Singh, V Kochat, E Arslan, S Satpati, W Deng, S Yadav, E Bataki, C Yee, ... Cancer Research 84 (6_Supplement), 7547-7547, 2024 | | 2024 |
| Epigenetic Scarring Leads to Irreversible NK Cell Dysfunction in Myeloid Malignancies B Kumar, A Singh, R Basar, N Uprety, Y Li, H Fan, M Shanley, S Acharya, ... Blood 142, 2088, 2023 | | 2023 |
| HETEROCHROMATIN DYSFUNCTION IMPACTING GENOMIC TOPOLOGY AND SUPERENHANCER LANDSCAPES PROMOTES ATRX-DEFICIENT GLIOMAGENESIS PB Malgulwar, AK Saw, A Singh, C Danussi, S Dharmaiah, WE Johnson, ... NEURO-ONCOLOGY 25, 2023 | | 2023 |
